Pemphigus group: overview, epidemiology, mortality, and comorbidities

Area of Science:

• Dermatology
• Immunology
• Autoimmune Bullous Diseases

Background:

• Pemphigus encompasses rare autoimmune bullous diseases impacting skin and mucous membranes, characterized by chronic progression, significant morbidity, and mortality.
• Pathogenic autoantibodies against desmosomal proteins cause intraepidermal cleavage, leading to vesicles and erosions.
• Diagnosis relies on clinical presentation, histological cleavage patterns, and immunoserological identification of target antigens.

Purpose of the Study:

• To provide an overview of pemphigus subtypes, including pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, pemphigus herpetiformis, and IgA pemphigus.
• To summarize current knowledge on the epidemiology, mortality, and comorbidities associated with pemphigus.
• To highlight recent advancements in understanding these organ-specific autoimmune diseases.

Main Methods:

• Review of existing literature on pemphigus subtypes, epidemiology, and clinical outcomes.
• Synthesis of data on diagnostic criteria, including clinical, histological, and immunoserological analyses.
• Compilation of recent findings on mortality trends and associated comorbidities in pemphigus patients.

Main Results:

• Pemphigus subtypes exhibit distinct clinical and histological features, with specific autoantibody targets.
• Epidemiological data reveal significant global variations in pemphigus incidence and prevalence.
• Studies on comorbidities and mortality show evolving trends, influenced by diagnostic and therapeutic advancements.

Conclusions:

• Accurate diagnosis of pemphigus subtypes is crucial and achieved through a combination of clinical, histological, and immunoserological methods.
• Understanding the epidemiology and comorbidities of pemphigus is essential for improving patient outcomes and management strategies.
• Ongoing research continues to refine our knowledge of pemphigus, impacting prognosis and mortality rates.